HOWL
Werewolf Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+33/100
Last price
0.92
▼ 0.01 (1.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.93
Day high
0.94
Day low
0.91
Volume
279.15K
Market cap
$44.72M
P/E (TTM)
—
52W range
0.27 – 2.13
Trailing performance
Returnvs SPY
1W
+1.10%
-0.8%
1M
-4.76%
-5.9%
3M
+155.56%
+151.0%
6M
-8.00%
-26.2%
YTD
+45.11%
+30.9%
1Y
-55.12%
-71.5%
3Y
-57.01%
-139.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HOWL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 7, 26 | EVNIN LUKE BASIL Director |
SELL | 143.20K | $44.75K | Indirect |
| Jun 29, 26 | EVNIN LUKE BASIL Director |
SELL | 157.08K | $47.13K | Indirect |
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 416.91K | $145.92K | Indirect |
| Jun 16, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 448.84K | $173.76K | Indirect |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 678.23K | $253.57K | Indirect |
| Jun 9, 26 | EVNIN LUKE BASIL Director |
SELL | 76.93K | $28.46K | Indirect |
| Jun 8, 26 | EVNIN LUKE BASIL Director |
SELL | 105.56K | $43.03K | Indirect |
| Jun 3, 26 | EVNIN LUKE BASIL Director |
SELL | 139.80K | $63.63K | Indirect |
| May 29, 26 | EVNIN LUKE BASIL Director |
SELL | 141.11K | $66.20K | Indirect |
| May 26, 26 | EVNIN LUKE BASIL Director |
SELL | 191.76K | $86.56K | Indirect |
| May 20, 26 | EVNIN LUKE BASIL Director |
SELL | 171.05K | $76.36K | Indirect |
| May 13, 26 | EVNIN LUKE BASIL Director |
SELL | 44.68K | $24.13K | Indirect |
| May 12, 26 | EVNIN LUKE BASIL Director |
SELL | 407.57K | $280.21K | Indirect |
| May 12, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 565.17K | $390.69K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
EVNIN LUKE BASIL |
Director | — | Sale |
GADICKE ANSBERT S. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
MPM BIOVENTURES 2014,L.P. |
Unknown | — | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$44.72M
Enterprise value$22.73M
Revenue (TTM)$21.00M
Gross profit$-5.18M
EBITDA$-21.92M
Net income$-34.61M
EPS (TTM)$-0.73
Free cash flow$-12.23M
Total cash$21.99M
Total debt$0
Book value / share$0.34
Shares outstanding48.60M
Float45.38M
Short % of float4.24%
Dividend yield0.00%
Beta (5Y)0.51
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.56
PEG ratio—
Price / sales—
Price / book2.75
EV / revenue1.08
EV / EBITDA-1.04
Gross margin-24.69%
Operating margin40.65%
Profit margin-164.82%
Return on equity-119.86%
Return on assets-27.39%
Debt / equity—
Current ratio2.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $1.89M | $19.94M | $16.40M | -100.0% |
| Operating revenue | $0 | $1.89M | $19.94M | $16.40M | -100.0% |
| Research & development | $44.83M | $56.43M | $41.78M | $53.76M | -20.6% |
| Selling, general & admin | $15.85M | $19.05M | $18.67M | $18.70M | -16.8% |
| Total operating expense | $60.68M | $75.48M | $60.45M | $72.46M | -19.6% |
| Operating income | -$60.68M | -$73.59M | -$40.50M | -$56.06M | +17.6% |
| Net interest income | -$2.17M | $2.02M | $4.28M | $1.91M | -207.4% |
| Pre-tax income | -$60.82M | -$70.52M | -$37.37M | -$53.81M | +13.7% |
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M | +13.7% |
| Net income to common | -$60.82M | -$70.52M | -$37.37M | -$53.81M | +13.7% |
| Basic EPS | -1.32 | -1.63 | -1.05 | -1.86 | +19.0% |
| Diluted EPS | -1.33 | -1.63 | -1.05 | -1.86 | +18.4% |
| EBIT | -$55.55M | -$65.86M | -$34.23M | -$53.81M | +15.7% |
| EBITDA | -$53.91M | -$64.05M | -$32.47M | -$52.71M | +15.8% |
| Basic shares | 46.02M | 43.33M | 35.65M | 28.86M | +6.2% |
| Diluted shares | 46.81M | 43.86M | 35.65M | 28.86M | +6.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $57.05M | $111.00M | $134.34M | $129.31M | -48.6% |
| Cash & short-term investments | $57.05M | $111.00M | $134.34M | $129.31M | -48.6% |
| Total current assets | $58.59M | $113.07M | $138.37M | $140.20M | -48.2% |
| Property, plant & equipment | $9.90M | $12.32M | $14.85M | $17.45M | -19.6% |
| Total assets | $69.40M | $126.93M | $174.83M | $160.25M | -45.3% |
| Total current liabilities | $36.15M | $15.18M | $19.38M | $23.99M | +138.1% |
| Current debt | $28.24M | — | $6.67M | — | — |
| Long-term debt | — | $26.09M | $32.66M | — | — |
| Total debt | $37.67M | $37.09M | $51.92M | $14.68M | +1.6% |
| Total liabilities | $44.59M | $53.54M | $63.46M | $37.91M | -16.7% |
| Retained earnings | -$475.41M | -$414.59M | -$344.07M | -$306.70M | -14.7% |
| Shareholder equity | $24.80M | $73.39M | $111.37M | $122.34M | -66.2% |
| Working capital | $22.44M | $97.89M | $118.99M | $116.21M | -77.1% |
| Net tangible assets | $24.80M | $73.39M | $111.37M | $122.34M | -66.2% |
| Shares issued | 48.60M | 44.83M | 39.11M | 31.43M | +8.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M | — | +13.7% |
| Depreciation & amortisation | $1.63M | $1.81M | $1.76M | $1.10M | — | -9.9% |
| Stock-based compensation | $6.25M | $8.83M | $8.01M | $7.40M | — | -29.2% |
| Change in working capital | -$8.21M | $2.53M | -$5.89M | $2.54M | — | -424.8% |
| Operating cash flow | -$60.29M | -$56.19M | -$32.61M | -$40.60M | — | -7.3% |
| Capital expenditure | — | -$254.00K | -$769.00K | -$3.61M | -$498.00K | — |
| Investing cash flow | $0 | -$254.00K | -$769.00K | -$3.61M | — | +100.0% |
| Financing cash flow | $6.03M | $13.08M | $58.43M | $15.91M | — | -53.9% |
| Free cash flow | -$60.29M | -$56.44M | -$33.38M | -$44.21M | — | -6.8% |
| End cash position | $57.95M | $112.22M | $155.58M | $130.53M | — | -48.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $21.00M | $0 | $0 | $0 | $0 | — |
| Operating revenue | $21.00M | $0 | $0 | $0 | $0 | — |
| Research & development | $6.16M | $8.18M | $6.93M | $11.63M | $13.14M | -24.7% |
| Selling, general & admin | $7.68M | $5.09M | $2.48M | $4.09M | $4.40M | +50.9% |
| Total operating expense | $13.84M | $13.27M | $9.42M | $15.73M | $17.54M | +4.3% |
| Operating income | $7.16M | -$13.27M | -$9.42M | -$15.73M | -$17.54M | +153.9% |
| Net interest income | -$198.00K | -$935.00K | -$805.00K | -$644.00K | -$451.00K | +78.8% |
| Pre-tax income | $3.67M | -$13.53M | -$8.38M | -$16.37M | -$17.98M | +127.1% |
| Net income | $3.67M | -$13.53M | -$8.38M | -$16.37M | -$17.98M | +127.1% |
| Net income to common | $3.67M | -$13.53M | -$8.38M | -$16.37M | -$17.98M | +127.1% |
| Basic EPS | 0.08 | -0.28 | -0.17 | -0.36 | -0.40 | +128.6% |
| Diluted EPS | 0.08 | -0.28 | -0.20 | -0.36 | -0.40 | +128.6% |
| EBIT | $4.14M | -$12.16M | -$7.01M | -$15.03M | -$16.68M | +134.1% |
| EBITDA | $6.60M | -$11.77M | -$6.61M | -$14.63M | -$16.27M | +156.1% |
| Basic shares | 48.60M | 48.60M | 48.43M | 45.80M | 44.98M | +0.0% |
| Diluted shares | 48.60M | 49.39M | 49.22M | 45.80M | 44.98M | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.99M | $46.45M | $57.05M | $65.71M | $77.60M | — | -52.7% |
| Cash & short-term investments | $21.99M | $46.45M | $57.05M | $65.71M | $77.60M | — | -52.7% |
| Total current assets | $22.89M | $48.73M | $58.59M | $68.17M | $80.44M | — | -53.0% |
| Property, plant & equipment | $1.26M | $9.29M | $9.90M | $10.51M | $11.11M | — | -86.4% |
| Total assets | $24.16M | $58.02M | $69.40M | $79.63M | $92.57M | — | -58.4% |
| Total current liabilities | $7.86M | $38.52M | $36.15M | $17.60M | $15.17M | — | -79.6% |
| Current debt | — | $28.83M | $28.24M | $6.00M | $2.40M | — | — |
| Long-term debt | — | — | — | $21.66M | $24.70M | $26.59M | — |
| Total debt | $0 | $37.65M | $37.67M | $37.30M | $37.15M | — | -100.0% |
| Total liabilities | $7.86M | $45.82M | $44.59M | $50.01M | $51.10M | — | -82.8% |
| Retained earnings | -$485.27M | -$488.94M | -$475.41M | -$467.03M | -$450.66M | — | +0.8% |
| Shareholder equity | $16.29M | $12.20M | $24.80M | $29.61M | $41.46M | — | +33.5% |
| Working capital | $15.03M | $10.21M | $22.44M | $50.57M | $65.27M | — | +47.1% |
| Net tangible assets | $16.29M | $12.20M | $24.80M | $29.61M | $41.46M | — | +33.5% |
| Shares issued | 48.60M | 48.60M | 48.60M | 47.27M | 45.34M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $3.67M | -$13.53M | -$8.38M | -$16.37M | -$17.98M | — | +127.1% |
| Depreciation & amortisation | $2.45M | $398.00K | $400.00K | $402.00K | $406.00K | — | +516.1% |
| Stock-based compensation | $419.00K | $929.00K | $1.21M | $1.23M | $1.79M | — | -54.9% |
| Change in working capital | -$2.52M | $1.47M | -$3.19M | -$1.15M | -$75.00K | — | -271.2% |
| Operating cash flow | $6.63M | -$10.60M | -$11.02M | -$15.16M | -$15.16M | — | +162.6% |
| Investing cash flow | — | — | $0 | $0 | $0 | $0 | — |
| Financing cash flow | — | — | $2.37M | $3.27M | $388.00K | $0 | — |
| Free cash flow | $6.63M | -$10.60M | -$11.02M | -$15.16M | -$15.16M | — | +162.6% |
| End cash position | $21.99M | $47.35M | $57.95M | $66.61M | $78.49M | — | -53.6% |
Options analytics
Put / call volume
0.02
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-45.7% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
130
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
1.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.32 | 0.14 | +145.2% |
| Mar 2026 | -0.30 | -0.28 | +5.1% |
| Dec 2025 | -0.35 | -0.17 | +51.0% |
| Sep 2025 | -0.38 | -0.36 | +5.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 1 | $0 | — |
| Next quarter | -0.17 | 1 | $0 | — |
| Current year | -0.89 | 1 | $0 | 0.0% |
| Next year | -0.59 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$7.00
High target$10.00
Low target$4.00
Implied upside660.87%
Analyst count3
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders6.62%
Held by institutions39.10%
Institutions holding58
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.94
-1.63% from price
SMA 20
0.95
-3.34% from price
SMA 50
0.75
+21.97% from price
SMA 100
0.57
+60.37% from price
SMA 200
0.65
+41.88% from price
EMA 12
0.93
-1.25% from price
EMA 26
0.90
+2.50% from price
EMA 50
0.80
+14.94% from price
RSI (14)
54.3
Neutral
MACD (12,26,9)
0.03
Hist -0.02
ATR (14)
0.04
4.41% of price
Realised vol 30D
53.2%
Annualised
Bollinger upper
1.01
20, 2σ
Bollinger lower
0.89
20, 2σ
50 / 200 cross
Golden
0.75 vs 0.65
Trend bias
Above 200
+41.88%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.00
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
53.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-84.8%
Peak to trough
Max drawdown 5Y
-98.2%
Peak to trough
ATR 14
0.04
4.41% of price
Beta (reported)
0.51
5Y monthly, from filing
Short interest
Shares short
1.71M
Prior 1.07M
Change vs prior
+59.8%
Shorts adding
% of float
4.24%
Normal
% of shares out
3.51%
Against total outstanding
Days to cover
0.1
Liquid
Float
45.38M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 18, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 25, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 21, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| May 9, 25 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 12, 25 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 14, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Nov 19, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 2, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 26, 24 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jun 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-4 · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-08-21
Corporate Changes & Voting Matters
8-K · 2026-08-20
Periodic Financial Reports
10-Q · 2026-07-31
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-03-27
Corporate Changes & Voting Matters
8-K · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-02-13
Headlines
1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost
Barchart · 42d ago
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
Barchart · 47d ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 47d ago
BC-Most Active Stocks
Associated Press · 47d ago
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing
InvestorsHub · 47d ago
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
MT Newswires · 47d ago
Werewolf Therapeutics to Merge With Ambros Therapeutics in All-Stock Deal
MT Newswires · 47d ago
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
GlobeNewswire · 47d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.